Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON -0.45%96 EV-to-FCF is 26.20 as of Jul. 25, 2026, which is 10% above its 10-year median of 23.92. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,019.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 568 Drug Manufacturers companies, Highnoon Laboratories ranks worse than 56.69% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Highnoon Laboratories's Enterprise Value is ₨47,523 Mil.
Highnoon Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₨1,814 Mil. Therefore, Highnoon Laboratories's EV-to-FCF for today is 26.20.
The historical rank and industry rank for Highnoon Laboratories's EV-to-FCF or its related term are showing as below:
KAR:HINOON'
s EV-to-FCF Range Over the Past 10 Years
Min: -19.52 Med: 23.92 Max: 303.61
Current: 26.2
During the past 13 years, the highest EV-to-FCF of Highnoon Laboratories was 303.61. The lowest was -19.52. And the median was 23.92.
KAR:HINOON's EV-to-FCF is ranked worse than 56.69% of 568
companies
in the Drug Manufacturers industry
Industry Median: 21.015
vs KAR:HINOON: 26.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Highnoon Laboratories's PE Ratio (TTM) for today is calculated as:
Highnoon Laboratories's share price for today is ₨961.21.
Highnoon Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨75.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HINOON vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's EV-to-FCF falls into.
Highnoon Laboratories's current Enterprise Value is ₨47,523 Mil.
Highnoon Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨1,814 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Highnoon Laboratories (KAR:HINOON) has a EV-to-FCF of 26.20 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Highnoon Laboratories and its competitors. This is 10% above median its historical median of 23.92. According to the industry distribution chart, Highnoon Laboratories ranks #322 out of 568 companies in the Drug Manufacturers industry, placing it in the top 56.7%.
Is Highnoon Laboratories' EV-to-FCF too high?
Highnoon Laboratories' current EV-to-FCF of 26.20 is 10% above median its 10-year median of 23.92. The Drug Manufacturers industry median EV-to-FCF is 21.02. Highnoon Laboratories' value of 26.20 is 24.7% above this industry median. Based on the distribution chart, Highnoon Laboratories ranks #322 out of 568 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #322 out of 568 companies for EV-to-FCF. This places Highnoon Laboratories in the lower half of its industry. The industry median EV-to-FCF is 21.02. Highnoon Laboratories' value of 26.20 is 24.7% above this benchmark. While the company's 10-year median is 23.92 vs. the industry median of 21.02, Highnoon Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.02, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current EV-to-FCF of 26.20 is 24.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current EV-to-FCF is 26.20, which is 10% above median its own 10-year median of 23.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,019.72, compared to a current price of ₨961.21 — trading 5.7% below its estimated fair value. The current EV-to-FCF is 26.20, which is 10% above median its 10-year median of 23.92 and 24.7% above the Drug Manufacturers industry median of 21.02. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current EV-to-FCF is 26.20 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨961.21 is trading 5.7% below its estimated GF Value™ of ₨1,019.72.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
EV-to-FCF: 26.20 (10% above median its 10-year median of 23.92)
GF Value™: ₨1,019.72 vs. price of ₨961.21 (5.7% below fair value)
Industry Position: 24.7% above the Drug Manufacturers median (#322 of 568)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
